Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Adverum Biotechnologies I...

    NASDAQ: ADVM · Real-Time Price · USD
    2.45
    -0.01 (-0.41%)
    At close: Jun 16, 2025, 11:09 AM

    Adverum Biotechnologies Statistics

    Share Statistics

    Adverum Biotechnologies has 20.89M shares outstanding. The number of shares has increased by 0.22% in one year.

    Shares Outstanding

    n/a
    		 20.89M

    Shares Change (YoY)

    n/a
    		 0.22%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 76.04%

    Shares Floating

    n/a
    		 13.83M

    Failed to Deliver (FTD) Shares

    n/a
    		 22

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 1.94M, so 9.3% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.94M

    Short % of Shares Out

    n/a
    		 9.3%

    Short % of Float

    n/a
    		 10.61%

    Short Ratio (days to cover)

    n/a
    		 8.6

    Valuation Ratios

    The PE ratio is -0.71 and the forward PE ratio is -0.7. Adverum Biotechnologies's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -0.71

    Forward PE

    n/a
    		 -0.7

    PS Ratio

    n/a
    		 92.38

    Forward PS

    n/a
    		 0.5

    PB Ratio

    n/a
    		 1.31

    P/FCF Ratio

    n/a
    		 -0.99

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Adverum Biotechnologies.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.73, with a Debt / Equity ratio of 1.3.

    Current Ratio

    n/a
    		 5.73

    Quick Ratio

    n/a
    		 5.73

    Debt / Equity

    n/a
    		 1.3

    Debt / EBITDA

    n/a
    		 -0.72

    Debt / FCF

    n/a
    		 -0.99

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $6,451.61

    Profits Per Employee

    n/a
    		 $-844,690.32

    Employee Count

    n/a
    		 155

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -67.85% in the last 52 weeks. The beta is 0.7, so Adverum Biotechnologies's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.7

    52-Week Price Change

    n/a
    		 -67.85%

    50-Day Moving Average

    n/a
    		 2.83

    200-Day Moving Average

    n/a
    		 5.09

    Relative Strength Index (RSI)

    n/a
    		 45.26

    Average Volume (20 Days)

    n/a
    		 335,728

    Income Statement

    In the last 12 months, Adverum Biotechnologies had revenue of 1M and earned -130.93M in profits. Earnings per share was -6.62.

    Revenue

    n/a
    		 1M

    Gross Profit

    n/a
    		 -2.65M

    Operating Income

    n/a
    		 -139.16M

    Net Income

    n/a
    		 -130.93M

    EBITDA

    n/a
    		 -127.27M

    EBIT

    n/a
    		 -139.16M

    Earnings Per Share (EPS)

    n/a
    		 -6.62
    Full Income Statement

    Balance Sheet

    The company has 60.65M in cash and 91.7M in debt, giving a net cash position of -31.05M.

    Cash & Cash Equivalents

    n/a
    		 60.65M

    Total Debt

    n/a
    		 91.7M

    Net Cash

    n/a
    		 -31.05M

    Retained Earnings

    n/a
    		 -1.07B

    Total Assets

    n/a
    		 137.65M

    Working Capital

    n/a
    		 64.38M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -92.46M and capital expenditures -388K, giving a free cash flow of -92.85M.

    Operating Cash Flow

    n/a
    		 -92.46M

    Capital Expenditures

    n/a
    		 -388K

    Free Cash Flow

    n/a
    		 -92.85M

    FCF Per Share

    n/a
    		 -4.69
    Full Cash Flow Statement

    Margins

    Gross margin is -265.3%, with operating and profit margins of -13915.9% and -13092.7%.

    Gross Margin

    n/a
    		 -265.3%

    Operating Margin

    n/a
    		 -13915.9%

    Pretax Margin

    n/a
    		 -13092.7%

    Profit Margin

    n/a
    		 -13092.7%

    EBITDA Margin

    n/a
    		 -12727.4%

    EBIT Margin

    n/a
    		 -13915.9%

    FCF Margin

    n/a
    		 -9285%

    Dividends & Yields

    ADVM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ADVM is $31.5, which is 1185.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $31.5

    Price Target Difference

    n/a
    		 1185.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 21, 2024. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Mar 21, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -12.61

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist